Does the media prefer ROIV or COGT?

In the previous week, Roivant Sciences had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 12 mentions for Roivant Sciences and 9 mentions for Cogent Biosciences. Roivant Sciences' average media sentiment score of 1.59 beat Cogent Biosciences' score of 0.69 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cogent Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer COGT or INSM?

In the previous week, Insmed had 16 more articles in the media than Cogent Biosciences. MarketBeat recorded 25 mentions for Insmed and 9 mentions for Cogent Biosciences. Insmed's average media sentiment score of 1.22 beat Cogent Biosciences' score of 0.69 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 18 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to COGT or MRNA?

In the previous week, Moderna had 10 more articles in the media than Cogent Biosciences. MarketBeat recorded 19 mentions for Moderna and 9 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.69 beat Moderna's score of 0.57 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Is COGT or VTRS more profitable?

Cogent Biosciences has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Viatris -2.04% 19.04% 7.62%

Does the media refer more to GMAB or COGT?

In the previous week, Cogent Biosciences had 5 more articles in the media than Genmab A/S. MarketBeat recorded 9 mentions for Cogent Biosciences and 4 mentions for Genmab A/S. Cogent Biosciences' average media sentiment score of 0.69 beat Genmab A/S's score of 0.47 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cogent Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cogent Biosciences (COGT) Competitors

$33.10 +0.48 (+1.47%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$33.50 +0.40 (+1.21%)

As of 06/12/2026 05:48 PM Eastern

Compare

COGT vs. ROIV, INSM, MRNA, VTRS, and GMAB

Should you buy Cogent Biosciences stock or one of its competitors? MarketBeat compares Cogent Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cogent Biosciences include Roivant Sciences (ROIV), Insmed (INSM), Moderna (MRNA), Viatris (VTRS), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical products" industry.

How does Cogent Biosciences compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

64.8% of Roivant Sciences shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cogent Biosciences has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Cogent Biosciences	N/A	-104.27%	-54.64%

Roivant Sciences currently has a consensus target price of $33.59, suggesting a potential upside of 11.82%. Cogent Biosciences has a consensus target price of $43.73, suggesting a potential upside of 32.11%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Roivant Sciences has higher revenue and earnings than Cogent Biosciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,615.84	-$299.77M	-$0.60	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

In the previous week, Roivant Sciences had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 12 mentions for Roivant Sciences and 9 mentions for Cogent Biosciences. Roivant Sciences' average media sentiment score of 1.59 beat Cogent Biosciences' score of 0.69 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cogent Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Summary

Roivant Sciences beats Cogent Biosciences on 11 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Insmed?

Cogent Biosciences (NASDAQ:COGT) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Cogent Biosciences has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Cogent Biosciences' return on equity of -104.27% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Insmed	-144.44%	-130.11%	-51.57%

Cogent Biosciences currently has a consensus price target of $43.73, suggesting a potential upside of 32.11%. Insmed has a consensus price target of $212.50, suggesting a potential upside of 117.17%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Cogent Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

In the previous week, Insmed had 16 more articles in the media than Cogent Biosciences. MarketBeat recorded 25 mentions for Insmed and 9 mentions for Cogent Biosciences. Insmed's average media sentiment score of 1.22 beat Cogent Biosciences' score of 0.69 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	18 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Insmed	$606.42M	34.97	-$1.28B	-$5.75	N/A

Summary

Insmed beats Cogent Biosciences on 8 of the 14 factors compared between the two stocks.

How does Cogent Biosciences compare to Moderna?

Cogent Biosciences (NASDAQ:COGT) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

75.3% of Moderna shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cogent Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Cogent Biosciences has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Moderna	-143.55%	-26.64%	-19.32%

Cogent Biosciences has higher earnings, but lower revenue than Moderna. Cogent Biosciences is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Moderna	$1.94B	10.19	-$2.82B	-$8.15	N/A

In the previous week, Moderna had 10 more articles in the media than Cogent Biosciences. MarketBeat recorded 19 mentions for Moderna and 9 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.69 beat Moderna's score of 0.57 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Cogent Biosciences presently has a consensus target price of $43.73, indicating a potential upside of 32.11%. Moderna has a consensus target price of $36.60, indicating a potential downside of 26.67%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Cogent Biosciences is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Summary

Cogent Biosciences and Moderna tied by winning 8 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Viatris?

Cogent Biosciences (NASDAQ:COGT) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Cogent Biosciences has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Viatris	$14.30B	1.34	-$3.51B	-$0.26	N/A

Cogent Biosciences has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Viatris	-2.04%	19.04%	7.62%

79.9% of Viatris shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cogent Biosciences presently has a consensus price target of $43.73, indicating a potential upside of 32.11%. Viatris has a consensus price target of $17.50, indicating a potential upside of 6.19%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cogent Biosciences is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Cogent Biosciences had 8 more articles in the media than Viatris. MarketBeat recorded 9 mentions for Cogent Biosciences and 1 mentions for Viatris. Viatris' average media sentiment score of 1.87 beat Cogent Biosciences' score of 0.69 indicating that Viatris is being referred to more favorably in the news media.

Company	Overall Sentiment
Cogent Biosciences	Positive
Viatris	Very Positive

Cogent Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Summary

Cogent Biosciences beats Viatris on 9 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Genmab A/S has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.20	$963M	$1.32	19.00
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Genmab A/S presently has a consensus target price of $37.93, suggesting a potential upside of 51.23%. Cogent Biosciences has a consensus target price of $43.73, suggesting a potential upside of 32.11%. Given Genmab A/S's higher possible upside, equities research analysts clearly believe Genmab A/S is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Genmab A/S has a net margin of 21.05% compared to Cogent Biosciences' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Cogent Biosciences	N/A	-104.27%	-54.64%

In the previous week, Cogent Biosciences had 5 more articles in the media than Genmab A/S. MarketBeat recorded 9 mentions for Cogent Biosciences and 4 mentions for Genmab A/S. Cogent Biosciences' average media sentiment score of 0.69 beat Genmab A/S's score of 0.47 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cogent Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Cogent Biosciences on 10 of the 16 factors compared between the two stocks.

Get Cogent Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COGT vs. The Competition

Export

Metric	Cogent Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.66B	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-15.25	19.82	24.21	24.42
Price / Sales	N/A	305.72	512.05	109.98
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	8.62	8.32	10.66	6.83
Net Income	-$328.94M	$23.94M	$3.57B	$337.67M
7 Day Performance	6.71%	3.53%	0.84%	2.68%
1 Month Performance	-3.19%	-2.55%	-0.34%	1.56%
1 Year Performance	367.51%	44.82%	25.40%	30.59%

Cogent Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COGT Cogent Biosciences	2.6426 of 5 stars	$33.10 +1.5%	$43.73 +32.1%	+367.5%	$5.66B	N/A	N/A	80	News Coverage
ROIV Roivant Sciences	2.2842 of 5 stars	$28.49 -0.3%	$33.59 +17.9%	+165.4%	$20.56B	$8.26M	N/A	860	Positive News
INSM Insmed	3.4261 of 5 stars	$94.17 -0.1%	$212.50 +125.7%	-0.9%	$20.42B	$606.42M	N/A	1,664	Positive News Analyst Forecast Options Volume
MRNA Moderna	1.3149 of 5 stars	$47.60 +0.3%	$36.60 -23.1%	+87.1%	$18.82B	$1.94B	N/A	4,700
VTRS Viatris	3.2321 of 5 stars	$15.93 +0.3%	$17.50 +9.9%	+84.8%	$18.49B	$14.30B	N/A	30,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COGT) was last updated on 6/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cogent Biosciences (COGT) Competitors

COGT vs. ROIV, INSM, MRNA, VTRS, and GMAB

How does Cogent Biosciences compare to Roivant Sciences?

Summary

How does Cogent Biosciences compare to Insmed?

Summary

How does Cogent Biosciences compare to Moderna?

Summary

How does Cogent Biosciences compare to Viatris?

Summary

How does Cogent Biosciences compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cogent Biosciences (COGT) Competitors

COGT vs. ROIV, INSM, MRNA, VTRS, and GMAB

How does Cogent Biosciences compare to Roivant Sciences?

Do insiders and institutionals hold more shares of ROIV or COGT?

Is ROIV or COGT more profitable?

Do analysts rate ROIV or COGT?

Which has preferable valuation & earnings, ROIV or COGT?

Does the media prefer ROIV or COGT?

Which has more risk and volatility, ROIV or COGT?

Summary

How does Cogent Biosciences compare to Insmed?

Is COGT or INSM more profitable?

Do analysts prefer COGT or INSM?

Which has more risk and volatility, COGT or INSM?

Does the media prefer COGT or INSM?

Which has preferable valuation and earnings, COGT or INSM?

Summary

How does Cogent Biosciences compare to Moderna?

Do insiders & institutionals believe in COGT or MRNA?

Which has more volatility and risk, COGT or MRNA?

Is COGT or MRNA more profitable?

Which has better valuation and earnings, COGT or MRNA?

Does the media refer more to COGT or MRNA?

Do analysts rate COGT or MRNA?

Summary

How does Cogent Biosciences compare to Viatris?

Which has higher earnings & valuation, COGT or VTRS?

Is COGT or VTRS more profitable?

Do insiders & institutionals believe in COGT or VTRS?

Do analysts prefer COGT or VTRS?

Does the media prefer COGT or VTRS?

Which has more volatility & risk, COGT or VTRS?

Summary

How does Cogent Biosciences compare to Genmab A/S?

Do institutionals and insiders have more ownership in GMAB or COGT?

Which has more risk and volatility, GMAB or COGT?

Which has stronger earnings and valuation, GMAB or COGT?

Do analysts prefer GMAB or COGT?

Is GMAB or COGT more profitable?

Does the media refer more to GMAB or COGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools